TY - JOUR
T1 - Relationship between obesity and clinical outcome in adults with acute myeloid leukemia
T2 - A pooled analysis from four CALGB (alliance) clinical trials
AU - Castillo, Jorge J.
AU - Mulkey, Flora
AU - Geyer, Susan
AU - Kolitz, Jonathan E.
AU - Blum, William
AU - Powell, Bayard L.
AU - George, Stephen L.
AU - Larson, Richard A.
AU - Stone, Richard M.
N1 - Funding Information:
National Cancer Institute of the National Institutes of Health; Contract grant numbers: U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology).
Funding Information:
National Cancer Institute of the National Institutes of Health; Contract grant numbers: U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology).
Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Obesity has been previously suggested as an adverse prognostic marker in patients with acute leukemia. To evaluate the relationship between obesity and clinical outcome, disease-free survival (DFS) and overall survival (OS), in patients with acute myelogenous leukemia (AML), including acute promyelocytic leukemia (APL), we performed a pooled analysis of four CALGB (Alliance) clinical trials. Our study included 446 patients with APL from CALGB 9710, and 1,648 patients between 18 and 60 years of age with non-APL AML from CALGB 9621, 10503, and 19808. Obesity was defined as BMI ≥30 kg/m2. Multivariate Cox proportional-hazard regression models were fitted for DFS and OS. Obesity was seen in 50% and 38% of APL and non-APL AML patients, respectively. In APL patients, obesity was associated with worse DFS (HR 1.53, 95% CI 1.03-2.27; P = 0.04) and OS (HR 1.72, 95% CI 1.15-2.58; P = 0.01) after adjusting for age, sex, performance status, race, ethnicity, treatment arm and baseline white blood cell count. Obesity was not significantly associated with DFS or OS in the non-APL AML patients. In conclusion, our study indicates that obesity has significant prognostic value for DFS and OS in APL patients, but not for non-APL AML patients.
AB - Obesity has been previously suggested as an adverse prognostic marker in patients with acute leukemia. To evaluate the relationship between obesity and clinical outcome, disease-free survival (DFS) and overall survival (OS), in patients with acute myelogenous leukemia (AML), including acute promyelocytic leukemia (APL), we performed a pooled analysis of four CALGB (Alliance) clinical trials. Our study included 446 patients with APL from CALGB 9710, and 1,648 patients between 18 and 60 years of age with non-APL AML from CALGB 9621, 10503, and 19808. Obesity was defined as BMI ≥30 kg/m2. Multivariate Cox proportional-hazard regression models were fitted for DFS and OS. Obesity was seen in 50% and 38% of APL and non-APL AML patients, respectively. In APL patients, obesity was associated with worse DFS (HR 1.53, 95% CI 1.03-2.27; P = 0.04) and OS (HR 1.72, 95% CI 1.15-2.58; P = 0.01) after adjusting for age, sex, performance status, race, ethnicity, treatment arm and baseline white blood cell count. Obesity was not significantly associated with DFS or OS in the non-APL AML patients. In conclusion, our study indicates that obesity has significant prognostic value for DFS and OS in APL patients, but not for non-APL AML patients.
UR - http://www.scopus.com/inward/record.url?scp=84956645738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956645738&partnerID=8YFLogxK
U2 - 10.1002/ajh.24230
DO - 10.1002/ajh.24230
M3 - Article
C2 - 26526191
AN - SCOPUS:84956645738
SN - 0361-8609
VL - 91
SP - 199
EP - 204
JO - American journal of hematology
JF - American journal of hematology
IS - 2
ER -